Nuveen
VIR icon

Nuveen’s Vir Biotechnology VIR Stock Holding History

Nuveen’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.2M Buy
1,982,942
+963,978
+95% +$9.17M ﹤0.01% 1255
2026
Q1 		$9.13M Buy
1,018,964
+453,420
+80% +$3.61M ﹤0.01% 1610
2025
Q4 		$3.41M Buy
565,544
+360,064
+175% +$2.14M ﹤0.01% 2077
2025
Q3 		$1.17M Hold
205,480
– – ﹤0.01% 2548
2025
Q2 		$1.04M Sell
205,480
-153,095
-43% -$821K ﹤0.01% 2586
2025
Q1 		$2.32M Sell
358,575
-997
-0.3% -$8.87K ﹤0.01% 2280
2024
Q4 		$2.64M Sell
359,572
-162,291
-31% -$1.28M ﹤0.01% 2269
2024
Q3 		$3.91M Buy
521,863
+305,653
+141% +$2.65M ﹤0.01% 2104
2024
Q2 		$1.92M Buy
216,210
+7,910
+4% +$75.9K ﹤0.01% 2414
2024
Q1 		$2.11M Hold
208,300
– – ﹤0.01% 2375
2023
Q4 		$2.1M Buy
208,300
+2,942
+1% +$26.9K ﹤0.01% 2392
2023
Q3 		$1.92M Sell
205,358
-1,378
-0.7% -$19.7K ﹤0.01% 2307
2023
Q2 		$5.07M Sell
206,736
-101,187
-33% -$2.54M ﹤0.01% 1902
2023
Q1 		$7.17M Sell
307,923
-185,799
-38% -$4.75M ﹤0.01% 1683
2022
Q4 		$12.5M Sell
493,722
-72,659
-13% -$1.78M ﹤0.01% 1347
2022
Q3 		$10.9M Sell
566,381
-99,846
-15% -$2.54M ﹤0.01% 1421
2022
Q2 		$17M Sell
666,227
-124,437
-16% -$2.91M 0.01% 1160
2022
Q1 		$20M Buy
790,664
+170,599
+28% +$5.06M 0.01% 1196
2021
Q4 		$26M Buy
620,065
+285,300
+85% +$11.2M 0.01% 1066
2021
Q3 		$14.6M Buy
334,765
+98,520
+42% +$4.27M ﹤0.01% 1500
2021
Q2 		$11.2M Buy
236,245
+5,118
+2% +$233K ﹤0.01% 1802
2021
Q1 		$11.8M Sell
231,127
-2,814
-1% -$152K ﹤0.01% 1691
2020
Q4 		$6.26M Sell
233,941
-95,707
-29% -$3.11M ﹤0.01% 1951
2020
Q3 		$11.3M Buy
329,648
+102,971
+45% +$4.43M ﹤0.01% 1445
2020
Q2 		$9.29M Buy
226,677
+189,973
+518% +$6.38M ﹤0.01% 1524
2020
Q1 		$1.26M Buy
36,704
+25,364
+224% +$682K ﹤0.01% 2410
2019
Q4 		$143K Buy
+11,340
New +$152K ﹤0.01% 3101

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen's VIR Position: Q2 2026 in Review

Nuveen increased its Vir Biotechnology (VIR) stake by 95% in Q2 2026, buying an estimated $9.17M and bringing the position to 1,982,942 shares worth $20.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1255.

Nuveen first reported a position in VIR in Q4 2019 and has held it in 27 quarters since. The position peaked at $26M in Q4 2021. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Nuveen held 1,982,942 shares of Vir Biotechnology worth $20.2M as of Q2 2026.
  • Nuveen bought 963,978 Vir Biotechnology shares in Q2 2026, an estimated $9.17M.
  • Vir Biotechnology made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1255 holding.
  • Nuveen first reported a position in Vir Biotechnology in Q4 2019 and has held it in 27 quarters since.
  • Nuveen's Vir Biotechnology position peaked at $26M in Q4 2021.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.